Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01108003
Other study ID # I 129408
Secondary ID NCI-2010-00759
Status Terminated
Phase N/A
First received April 19, 2010
Last updated November 19, 2015
Start date April 2010
Est. completion date October 2015

Study information

Verified date November 2015
Source Roswell Park Cancer Institute
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Rationale: Broccoli sprout extract contains ingredients that may prevent or slow the growth of certain cancers.

Purpose: This pilot study is studying the side effects of broccoli sprout extract in treating patients with transitional cell bladder cancer undergoing surgery.


Description:

Primary Objectives:

I. To determine the tolerability and toxicity of a broccoli sprout extract (providing 200 micro mol isothiocyanate/dose/per day) given for 14 days in patients destined to undergo definitive bladder resection for bladder cancer.

Secondary Objectives:

I. Establish the safety of administration of the broccoli extract on the bladder surgery specifically.

II. Determine the levels of isothiocyanates and their metabolites in urine, blood, benign urothelium and bladder cancer tissue.

III. Assess the antitumor effects of broccoli extract on the primary bladder tumor by measuring angiogenesis, cell proliferation and apoptosis.

IV. Determine the feasibility of treating patients with 200 micro mol isothiocyanate per dose per day of broccoli sprout extract in future therapeutic and prevention clinical trials.

Outline: Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 4 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date October 2015
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Any patient eligible for superficial bladder cancer

- Patients must be considered fit for surgical resection with curative intent

- No chemotherapy, surgery (excluding transurethral resection of bladder tumor [TURBT], BCG or radiotherapy in the prior 4 weeks [6 weeks for mitomycin C or interferon])

- No previous treatment/ingestion with broccoli extracts

- Eastern Oncology Group (ECOG) performance status 0-2

- AST and ALT =< 2.5 times ULN (upper limit of normal)

- Total bilirubin =< 2.0 mg/dL

- Creatinine Clearance >= 30 ml/min

- WBC > 3000 mm^3

- Absolute neutrophil count > 1000/mm^3

- Platelets > 100,000/mm^3

- All patients must sign a study-specific consent form indicating that they are aware of the investigational nature of this study

Exclusion Criteria:

- Have participated in any clinical trial involving conventional or investigational drugs or devices within the previous 4 weeks

- Prior radiation to the pelvis

- Intractable urinary tract infection that has not responded to antibiotic treatment

- Active, uncontrolled bacterial, viral, or fungal infection including HIV

- Have had major surgery within 4 weeks of starting therapy (not including placement of vascular access device or TURBT)

- Poor medical risk in the opinion of the treating oncologist due to non-malignant systemic disease

- Pregnant or lactating patients: patients must be postmenopausal or practicing an accepted form of birth control; for patients where pregnancy is a possibility, a pregnancy test will be required prior to initiation of therapy

- Have a history of myocardial infarction or angina pectoris/angina equivalent in the last 6 months (the patient may be on anti-anginal medications if the symptoms have been entirely controlled for greater than 6 months), or have uncontrolled congestive heart failure

- Have a history of bleeding disorders or thrombosis; patients on therapeutic doses of anticoagulation (including coumadin or heparins) are not permitted on trial (this exclusion criterion does not include those patients receiving low dose or prophylactic dose anticoagulation [i.e. coumadin 1 mg daily in patients with central intravenous lines])

- Radiotherapy during the course of the trial

- Inability to tolerate proposed treatment or procedures

- Have additional uncontrolled serious medical conditions or psychiatric illness

- Patients with a history of hepatitis (including but not exclusive to viral hepatitis auto-immune or alcoholic)

- Patients with active thyroid disease (patients with hypothyroidism, adequately replaced on a stable dose of thyroid replacement will be allowed on trial)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
broccoli sprout extract
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Roswell Park Cancer Institute Buffalo New York

Sponsors (3)

Lead Sponsor Collaborator
Roswell Park Cancer Institute Johns Hopkins University, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity as assessed by National Cancer Institute (NCI) Common Toxicity Criteria version 3.0 14 days Yes
Secondary Apoptosis, cell proliferation, and microvessel density 1 year No
See also
  Status Clinical Trial Phase
Completed NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Phase 1
Terminated NCT01118351 - Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer Phase 2
Terminated NCT00112905 - Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Phase 2
Completed NCT00072150 - Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma Phase 2
Completed NCT00028756 - Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Phase 3
Completed NCT02318329 - Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors Phase 1
Completed NCT00407485 - VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Phase 2
Withdrawn NCT01639521 - Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer Phase 2
Completed NCT00003167 - Gene Therapy in Treating Patients With Advanced Bladder Cancer Phase 1
Completed NCT03081858 - Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Phase 1/Phase 2
Completed NCT02101931 - A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Phase 3
Terminated NCT00859339 - Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC Phase 2
Completed NCT00005831 - Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Phase 2
Completed NCT00706641 - Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder N/A
Completed NCT01824329 - Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Phase 2
Terminated NCT00363883 - Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium Phase 2
Completed NCT00021099 - Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer Phase 2
Terminated NCT01382706 - Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder Phase 2
Terminated NCT01954173 - Adjuvant Radiation for High Risk Bladder Cancer N/A
Terminated NCT00004856 - Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium Phase 2